(Total Views: 138)
Posted On: 03/01/2019 12:57:41 AM
Post# of 154873
Very good article , sometimes I was smiling when reading ...mostly true , and mostly IMO obvious ...
Things I noticed specially for different reasons ....
" Higher dose is significant better , than the lower dose " ..... I agree except if side effects will happen !!
" If the doses are indistinguishable , the trial usually will be uninterpretable absent a placebo group "
And my most important is .......
" A common error in drug development to use a single dose or dose regimen in phase 3 trial ...
This design can either lead to disappointing efficacy results , or evaluation of an effective dose with undesirable safety issues , where another dose might have shown more acceptable risk - benefit characteristics "
Hopefully since Leronlimab is so far very safe , our safety margins are not that close !!!
Things I noticed specially for different reasons ....
" Higher dose is significant better , than the lower dose " ..... I agree except if side effects will happen !!
" If the doses are indistinguishable , the trial usually will be uninterpretable absent a placebo group "
And my most important is .......
" A common error in drug development to use a single dose or dose regimen in phase 3 trial ...
This design can either lead to disappointing efficacy results , or evaluation of an effective dose with undesirable safety issues , where another dose might have shown more acceptable risk - benefit characteristics "
Hopefully since Leronlimab is so far very safe , our safety margins are not that close !!!
(0)
(0)
